Recommendations for Use of Slow Release Oral Morphine as Opioids Agonist Therapy

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT). There is also a plain language summary of the recommendations, intended for patients interested in learning about SROM as OAT.